Argus analyst David Toung downgraded Integra LifeSciences (IART) to Hold from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences assumed with an Equal Weight at Wells Fargo
- Integra LifeSciences price target lowered to $9 from $11 at Citi
- Integra’s MicroMatrix Flex Study Reaches Completion, Setting Up Next Steps for IART Investors
- Integra Lifesciences Charts Cautious Path After Earnings
- Integra LifeSciences price target lowered to $11 from $13 at JPMorgan